Cytokinetics (CYTK) Preferred Dividend Payments (2011 - 2012)
Cytokinetics (CYTK) posted quarterly Preferred Dividend Payments of $1.3 million for Q2 2012, down 54.25% year-over-year from $2.9 million in Q3 2011, and down 54.25% quarter-over-quarter from $2.9 million in Q2 2011.
Cytokinetics (CYTK) Preferred Dividend Payments (2011 - 2012) Analysis & Trends
Cytokinetics (CYTK) has reported Preferred Dividend Payments for 2 consecutive years, with $1.3 million the latest figure, recorded in Q2 2012.
- In Q2 2012, Preferred Dividend Payments fell 54.25% year-over-year to $1.3 million; the TTM figure through Dec 2012 stood at $1.3 million (changed N/A YoY), while the FY2012 annual figure was $1.3 million, down 54.25% from the prior year.
- Preferred Dividend Payments fell to $1.3 million in Q2 2012 per CYTK's latest filing, from $2.9 million in the prior quarter.
- Across five years, Preferred Dividend Payments topped out at $2.9 million in Q2 2011 and bottomed at $1.3 million in Q2 2012.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Pref Dividends (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Cytokinetics | 10.31 Bn | 9.14 Bn | 25.89 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2012 | 1.31 Mn |
| Jun 30, 2011 | 2.86 Mn |